Following the publication of the ambitious plan or revision of the European Pharmaceutical Legislation by the European Commission, the European Expert Group of Orphan Drug Incentives will host its first signature event to reflect on how the Union can face the challenges ahead for people affected by rare
conditions and enablers of innovation. We will present our policy recommendations for an efficient revision of the OMP Regulation by focusing on modulation of market exclusivity, and we will officially launch our proposals for an EU HTA methodology for OMPs.

Join us for an event that brings together a diverse group of rare disease experts to discuss and propose policy recommendations for improving the European legislative framework for orphan drugs. With a focus on collaboration and consensus-building, this event is meant to create a meaningful dialogue and help chart a path forward for a more effective legislative and regulatory framework, capable of addressing the needs of people with rare conditions and boosting innovation.

Established in 2020, the European Expert Group on Orphan Drug Incentives (OD Expert Group) is a multidisciplinary and cross-functional expert group that brings together representatives of the broad rare disease community, including researchers, academia, patient representatives, members of the investor community, rare disease companies and trade associations. Our experts and representatives of the decision-making processes will explore ideas for navigating the challenges ahead, trying to address the question of how to create a resilient ecosystem for rare diseases.

Organised by: The European Expert Group on Orphan Drug Incentives (OD Expert Group)
Media Partner: EURACTIV